Prognosis in relapsed metastatic mind and neck squamous cell cancer (RM-HNSCC) is dismal. of Cetuximab combination [7]. Since then, the extreme regimen represents the new first-line standard of care for RM-HNC. An established second-line treatment has never existed in RM-HNC, up to the approval of immune checkpoint inhibitors (ICIs) [8]. Therefore, the 5-12 months prognosis… Continue reading Prognosis in relapsed metastatic mind and neck squamous cell cancer (RM-HNSCC)